

IFW

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))				Docket No. 2877	
In Re Application Of: OBENDORF, M., ET AL					
Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/791,017	03/02/2004		278		
Title: METHOD OFR DETERMINING HORMONAL EFFECT OF SUBSTANCES					
Address to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450					
37 CFR 1.97(b)					
1. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.					
37 CFR 1.97(c)					
2. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:					
<div style="margin-left: 40px;"> <input type="checkbox"/> the statement specified in 37 CFR 1.97(e); </div>					
OR					
<div style="margin-left: 40px;"> <input type="checkbox"/> the fee set forth in 37 CFR 1.17(p). </div>					

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
2877

In Re Application: **OBENDORF, M., ET AL**

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/791,017	03/02/2004		278		

METHOD OFR DETERMINING HORMONAL EFFECT OF SUBSTANCES

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☐ The Director is hereby authorized to charge and credit Deposit Account as described below.
- ☐ Charge the amount of _____
 - ☐ Credit any overpayment.
 - ☐ Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. _____).

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited on AUG. 4, 2004 th the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


Signature of Person Mailing Correspondence

MICHAEL J. STRIKER


Typed or Printed Name of Person Mailing Certificate

***This certificate may only be used if paying by deposit account.**


Signature

Dated: AUGUST 4, 2004

CC:



UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner:.

Group:

Attorney Docket # 2877

Applicant(s): OBENDORF, M., ETAL

Serial No.: 10/791,017

Filed: 03/02/2004

For : METHOD FOR DETERMINING HORMONAL EFFECT
OF SUBSTANCES

INFORMATION DISCLOSURE STATEMENT

August 3, 2004

Honorable Commissioner of Patents
and Trademarks
Washington, D.C. 20231

S I R S:

 X In accordance with the Duty of Disclosure, Applicant(s) submit(s) herewith a copy of a Foreign Search Report in a counterpart application and copies of the reference(s) indicated therein.

 X In the event that the Foreign Search Report is in a foreign language, a translation thereof is herewith submitted.

 X Attached hereto is a FORM PTO 1449 listing the references.

 Attached hereto is a copy of a reference cited in the specification of the application as filed. The specification itself recites the relevance of these documents, and pursuant to M.P.E.P. Section 609 A (3) this represents an acceptable Statement of Relevancy. The reference(s) appear(s) at the following page(s) and line(s) of the specification:

 Applicant petitions for consideration of this Information Disclosure Statement since it is being submitted after receipt of an office action. It is respectfully requested that the required fee be charged to the account of the undersigned: 19-4675.

page 2 of 2


- ☐ Attached hereto are copies of references cited which may be pertinent to this application. Since the references are in the English language, no statement of relevancy is submitted.
- ☐ Attached hereto is a copy of the Office Action issued in the corresponding German and European applications, together with a translation thereof and copies of the references cited therein. A list of the cited references is also attached.
- ☐ Attached hereto copies of references cited which may be pertinent to this application. An English translation of the reference is also attached.
- ☐ Attached hereto is a Statement of Relevancy and copies of references cited therein.
- ☐ Relevancy is indicated in an English language abstract attached hereto.

Respectfully submitted,


Michael J. Striker
Attorney for Applicant(s)
Reg. No. 27233

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



ATTY DOCKET NO.

2877

APPLICATION NO.

10/791,017

APPLICANT(S)

OBENDORF, M., ET AL

FILING DATE

03/02/2004

GROUP ART UNIT

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

U.S. PATENT APPLICATION PUBLICATIONS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	02/36621 A1	05/10/2002	WO (ENGLISH ABSTRACT)			✓	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		ARAYA NATSUMI ET AL: "COOPERATIVE INTERACTION OF..." JOURNAL OF BIOLOGICAL CHEMISTRY, VOL. 278, NO. 7, ISSUE OF FEB. 14, 2003, PP. 5427-5432.
		FELSCH JASON ET AL: "TYROSINE KINASE..." CURRENT BIOLOGY, BD. 9, NR. 9, MAY 6, 1999, PP. 485-488.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>				ATTY DOCKET NO. 2877		APPLICATION NO. 10/791,017	
				APPLICANT(S) OBENDORF, M., ET AL			
				FILING DATE 03/02/2004		GROUP ART UNIT	

U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

U.S. PATENT APPLICATION PUBLICATIONS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS								
*	EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>			
			MALTAIS A., ET AL: "THE AF2 DOMAIN OF THE ORPHAN NUCLEAR..." CANCER LETTERS, BD. 183, NR. 1, SEP. 8, 2002, PP. 87-94.
			VERMEULEN A. ET AL: "DIAGNOSIS OF HYPOGONADISM IN THE AGING MALE" AGING MALE 2002 UNITED KINGDOM, BD. 5, NR. 3, 2002, PP. 170-176.

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.